ChanTest Gets Equity Funds from Ampersand Ventures
 
ChanTest, a laboratory testing services company based in Cleveland, Ohio, announced this week that it has completed a private equity financing round with Wellesley, Mass.-based Ampersand Ventures.
 
This financing will enable ChanTest to pursue strategic investments that expand the company's offerings through its continued development of a library of ion channel-expressing cell lines.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.